Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.47 |
| ▸ | PIM1 | P11309 | 9/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15280689 | 0.87 | RET (0.48) | RETPIM1PIM2KDRIRAK4 | |
| SCHEMBL15261338 | 0.85 | RET (0.52) | RETPIM1PIM2NTRK1NTRK3 | |
| SCHEMBL29660320 | 0.81 | RET (0.75) | RETPIM1PIM2KDRAAK1 | |
| SCHEMBL29660271 | 0.81 | RET (0.59) | RETPIM1PIM2KDR | |
| SCHEMBL19467181 | 0.81 | RET (0.61) | RETPIM1PIM2KDR | |
| SCHEMBL16561406 | 0.80 | IRAK4 (0.34) | NTRK1NTRK3NTRK2IRAK4AAK1 | |
| SCHEMBL15280671 | 0.80 | FYN (0.48) | RETPIM1PIM2KDRAAK1 | |
| SCHEMBL29660274 | 0.80 | FYN (0.48) | RETPIM1PIM2KDRAAK1 | |
| SCHEMBL16561388 | 0.80 | IRAK4 (0.34) | NTRK1NTRK3NTRK2IRAK4AAK1 | |
| SCHEMBL19467005 | 0.78 | RET (0.57) | RETPIM1PIM2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834243-B1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170129896-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXION PHARMACEUTICALS INC (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129896-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXION PHARMACEUTICALS INC (US) | 2017-05-11 | — | — | US | disclosed |
| US-9403832-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403832-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150183792-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-07-02 | — | — | US | disclosed |
| US-20150183792-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-07-02 | — | — | US | disclosed |
| US-8946415-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946415-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183792-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | RET 376/4885PIM1 692/4885PIM2 837/4885 |
| US-20170129896-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | RET 376/4885PIM1 692/4885PIM2 837/4885 |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | RET 376/4885PIM1 692/4885PIM2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.